Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

ONO PHARMACEUTICAL CO., LTD. (4528)
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Financials (JPY)
Sales 2019 279 B
EBIT 2019 -
Net income 2019 53 113 M
Finance 2019 92 785 M
Yield 2019 1,71%
Sales 2020 311 B
EBIT 2020 -
Net income 2020 65 270 M
Finance 2020 115 B
Yield 2020 1,87%
P/E ratio 2019 26,18
P/E ratio 2020 21,15
EV / Sales2019 4,90x
EV / Sales2020 4,34x
Capitalization 1 462 B
More Financials
Company
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine.The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan. 
Sector
Pharmaceuticals
Calendar
-
More about the company
Surperformance© ratings of ONO PHARMACEUTICAL CO., LT
Trading Rating : Investor Rating :
More Ratings
Latest news on ONO PHARMACEUTICAL CO., LT
06/22ONO PHARMACEUTICAL : Notice of Resolutions Passed at The 70th Ordinary General S..
PU
06/05ONO PHARMACEUTICAL : Opdivo Plus Chemotherapy Showed Improved Progression-Free S..
PU
06/05ONO PHARMACEUTICAL : Opdivo (nivolumab) 3 mg/kg Demonstrates Sustained, Superior..
PU
06/05ONO PHARMACEUTICAL : Array BioPharma Announces Additional Median Overall Surviva..
PU
06/04ONO PHARMACEUTICAL : Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimuma..
PU
05/31Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Cons..
AQ
05/30ONO PHARMACEUTICAL : Announcement on Establishment of Immune-mediated Inflammato..
PU
05/25ONO PHARMACEUTICAL : and BMSKK Receive Approval for Opdivo® and Yervoy® Combinat..
PU
05/25ONO PHARMACEUTICAL : Notice to Convene the 70th Ordinary General Shareholders' M..
PU
05/07ONO PHARMACEUTICAL : European Medicines Agency Validates Bristol-Myers Squibb&rs..
PU
More news
Sector news : Generic Pharmaceuticals
06/22Federal Judge Gives Lilly Win on Alimta Regimen Patent
DJ
06/22JOHNSON & JOHNSON : Remakes Top Leadership -- Update
DJ
06/22JOHNSON & JOHNSON : Worldwide Chairman Peterson to Retire
DJ
06/22SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/22Roche to Appoint James Sabry as Head of Partnering
DJ
More sector news : Generic Pharmaceuticals
Latest Tweets
06/05ONO PHARMACEUTICAL : Array BioPharma Announces Additional Median Overall Surv.. 
05/25ONO PHARMACEUTICAL : and BMSKK Receive Approval for Opdivo® and Yervoy® Combi.. 
05/07ONO PHARMACEUTICAL : Karyopharm Announces Positive Top-Line Data from Phase 2.. 
04/19ONO PHARMACEUTICAL : U.S. Food and Drug Administration Accepts Supplemental B.. 
04/18ONO PHARMACEUTICAL : U.S. Food and Drug Administration Approves Opdivo® (nivo.. 
More tweets
Qtime:19
News from SeekingAlpha
04/303 THINGS IN BIOTECH, APRIL 29 : Bristol-Myers Widens, Ono Takes On Pheo, BrainSt.. 
03/23Alzheon Files To Raise $80 Million In U.S. IPO 
03/14Ono Pharma exercises option for Merus Biclonics technology for autoimmune bis.. 
2017Ono Pharmaceutical Needs To Reinvest Its Windfall 
2017YOUR DAILY PHARMA SCOOP : Axovant's Promised Upside, Gilead's Whistleblower Trou.. 
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Technical analysis trends ONO PHARMACEUTICAL CO., LT
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 3 218  JPY
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director & Executive Vice President
Isao Ono Director & Managing Executive Officer
Kei Sano Director & Senior Executive Officer